Date: 2015-12-22
Type of information: Company acquisition
Acquired company: Synabs (Belgium)
Acquiring company: Biotech Investissement (France)
Amount:
Terms: * On December 22, 2015, Biotech Investissement announced that the Belgium biotech company SynAbs is now a sister company of RD-Biotech and Diaclone (Biotech Investissement Group). As a spinoff of UCL (Université catholique de Louvain, Belgique), SynAbs received an exclusive license for the development and the marketing of rat monoclonal antibody technology and its worldwide renowned hybridoma collection generated by the CHEX laboratory over 25 years. The expertise of the SynAbs team and its hybridoma portfolio provides strong synergies within the Biotech Investissement group. The complementary nature of the two entities, SynAbs and Biotech Investissement, will make it possible to consolidate SynAbs’s activity in Belgium and to expand its sales network in France and the Netherlands.
Details: SynAbs is currently involved in the production of rat monoclonal antibodies, serving CROs (mAb and custom immunoassays) and with a product catalogue including more than a hundred secondary anti-immunoglobulins). SynAbs was set up in September 2015 out of Professor Pierre Gianello’s experimental
surgery laboratory (CHEX) in order to develop greater expertise in the production of monoclonal antibodies, essentially of rats but also of mice. The UCL spin-off was set up as a result of coordinated action by the laboratory, the Louvain Technology Transfer Office (LTTO), Wallonia Biotech Coaching and a French group, Biotech
Investissement (which owns RD Biotech and Diaclone).
Related: production manufacturing monoclonal antibody
